3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Leukemia
21
Lymphoma
7
Burkitt Lymphoma
6
Leukemia, Myeloid, Acute
5
Leukemia, Biphenotypic, Acute
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Anemia, Refractory, with Excess of Blasts
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Myeloproliferative Disorders
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Erythroblastic, Acute
2
Leukemia, Eosinophilic, Acute
2
Down Syndrome
2
Anemia, Refractory
2
Sarcoma, Myeloid
1
Recurrence
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Basophilic, Acute
1
Drug-Related Side Effects and Adverse Reactions
1
Dendritic Cell Sarcoma, Interdigitating
1
Congenital Abnormalities
1
Cardiotoxicity
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
Prednisone
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
atezolizumab
7
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
Asparaginase
×
Clear all
NCT03665441
2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3
Completed
512 enrolled
19 charts